OptiPharm Co

OptiPharm Co FCF Yield

The Free Cash Flow Yield of OptiPharm Co (153710.KQ) as of Nov 4, 2026 is -5.15 %. In the previous year, Free Cash Flow Yield was -2.93 % — a change of 75.82% (lower).

FCF Yield

-5.15 %

YoY

75.82%

Last updated:

Free Cash Flow Yield of OptiPharm Co is 2025 -5.15 % . Free Cash Flow Yield of OptiPharm Co was 2024 -2.93 % . It decreases by 75.82% lower compared to the previous year.

The OptiPharm Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
1.26 KRW
Jan 1, 2019
-0.22 KRW
Jan 1, 2020
-3.15 KRW
Jan 1, 2021
-3.42 KRW
Jan 1, 2022
-8.84 KRW
Jan 1, 2023
-4.34 KRW
Jan 1, 2024
-2.93 KRW
Jan 1, 2025
-5.15 KRW
The OptiPharm Co FCF Yield history
YEARFCF YieldYoY
-5.15 %+75.82%
-2.93 %-32.61%
-4.34 %-50.84%
-8.84 %+158.10%
-3.42 %+8.76%
-3.15 %+1,300.82%
-0.22 %-117.89%
1.26 %-344.32%
-0.51 %-187.23%
0.59 %-152.68%
-1.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiPharm Co Stock analysis

What does OptiPharm Co do? OptiPharm Co Ltd generates revenue through its Sale Business segment, which provides livestock disease appraisal services, distributes animal drugs, and manufactures and sells feed additives. The New Business segment develops heterologous organisms, VLP vaccines, and human diagnostic kits, including heterologous skin, xenogeneic islets, and xenogeneic corneal products, as well as VLP-based animal combined vaccines and HPV vaccines for humans. Human diagnostic kits target breast and cervical cancer reagents. Products are distributed domestically and internationally, serving both local and overseas markets. The company's primary customers are domestic and international buyers of pharmaceuticals, livestock health products, and diagnostic solutions. The Sale Business segment caters to agricultural and veterinary sectors, while the New Business segment serves healthcare providers and diagnostic laboratories. Revenue streams include product sales from both segments, with a focus on high-demand medical and animal health solutions. OptiPharm Co Ltd's business model relies on manufacturing and wholesaling pharmaceuticals, with the Sale Business segment emphasizing livestock health services and animal drug distribution, and the New Business segment focusing on innovative medical technologies. The firm's product portfolio spans from feed additives to advanced diagnostic kits, targeting both domestic and global markets for sustainable growth. OptiPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OptiPharm Co stock

Free Cash Flow Yield of OptiPharm Co is -5.15 % in 2025.

Free Cash Flow Yield of OptiPharm Co changed from -2.93 % to -5.15 %, representing a 75.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield OptiPharm Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's OptiPharm Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — OptiPharm Co

All Key Metrics — OptiPharm Co